USA Real Estate Holding Co. (USTC)

[rs99]

Merger with a worthless piece of paper that Jeffery already owns. I called him out on the Mid Atlantic Capital Assoc. finance scam that never happened and shares issued to Mid Atlantic on multiple occasions with two different companies. That forced him to file a Form 3 disclosing a 1/3 ownership in the company he was doing business with. That was another one of his SEC violations he got away with. Jeffery Bruhjell has a huge history of running stock scams like he is doing here. I have a lot more DD on him as well.


http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9101971

http://www.bizjournals.com/prnewswire/press_releases/2011/03/01/AQ56446


FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *
Bruhjell Jeffrey Roy

2. Date of Event Requiring Statement (MM/DD/YYYY)
3/20/2012

3. Issuer Name and Ticker or Trading Symbol
Global Immune Technologies Inc. [GIMU]

(Last) (First) (Middle)
2809 GREAT NORTHERN LOOP ST, SUITE 100

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__ X __ Director ___ X ___ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
Corporate Secretary & CFO /

(Street)
MISSOULA, MT 59808

(City) (State) (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)



6. Individual or Joint/Group Filing (Check Applicable Line)
_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 2. Amount of Securities Beneficially Owned
(Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 5694508 D
Common Stock 1000000 I One-third owner of Mid-Atlantic Capital Associates SA

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Bruhjell Jeffrey Roy
2809 GREAT NORTHERN LOOP ST
SUITE 100
MISSOULA, MT 59808 X X Corporate Secretary & CFO

Signatures
J R Bruhjell 2/20/2013
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Press Releases
Global Immune Technologies Finalizes Solar Deal With Germans
GLOBAL IMMUNE TECHNOLOGIES ISSUES SHARES

PR Newswire
WINDISCHLEUBE, Germany, March 1, 2011
WINDISCHLEUBE, Germany, March 1, 2011 /PRNewswire/ -- The Board of Directors of Global Immune Technologies, Inc. (OTB QB: GIMU) today announces that the deal originally announced on December 22, 2010 has been finalized with Mid Atlantic Capital Associates SL of Mallorca, Spain and Institute of Applied Technology of Germany previously announced. The Joint Venture agreed to has also been closed and the entity RenOnuG has been formed as a German company. The details of the JV were disclosed in our 8K filing of February 22nd.

On 15 February 2011 the Institute of Applied Technology was issued shares of common stock in the amount of 92,000,000 shares being approximately 80.08% of the then issued shares of common stock outstanding. Additionally 1,000,000 shares were paid as the fee for the deal to the seller, Mid Atlantic Capital Associates SL and a finder's fee of 5,694,508 shares were paid equalling less than 5% of the then issued and outstanding common stock. The Registrant now has 114,890,153 shares of common stock issued and outstanding with no change in the float estimated at approximately 11,000,000 shares.

An 8K will be filed shortly.

Further information can be obtained by phoning Jeffrey R. Bruhjell [phone]

Safe Harbour Statement

This communication contains statements that may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Global Immune Technologies, Inc. and members of its management as well as the assumptions on which such statements are based.

Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include fluctuation of operating results, the ability to compete successfully, and the ability to complete before-mentioned transactions.

The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

SOURCE Global Immune Technologies, Inc.